Clinical Trial Update: A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab [Phase 2]

View source ↗

Summary

Phase 2 trial studying nivolumab plus ipilimumab in advanced acral lentiginous melanoma and mucosal melanoma; terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acral Lentiginous Melanoma
• Mucosal Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Georgetown University | Conditions: Acral Lentiginous Melanoma, Mucosal Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2024-04-04